Real Answers to Real Questions
Tackle Real-World, Practical Questions that Endocrinologists and Endocrinology-focused HCPs Face Every Day
Once-weekly basal insulin regimens are poised to enter the treatment armamentarium for diabetes management. Gaps in understanding the unique molecular design contribute to therapeutic inertia and delayed implementation of a more convenient, flexible, and potentially safer alternative to daily insulin regimens for patients with T2D.
This event is designed for US-based endocrinologists and endocrinology-focused NPs and PAs involved in the management of patients with type 2 diabetes (T2D). Participants will gain actionable insights from expert faculty, who will explore:
- Differentiate emerging once-weekly basal insulins from traditional once-daily formulations based on molecular structure, mechanism of action, and pharmacokinetic/pharmacodynamic properties
- Interpret the efficacy and safety data of once-weekly basal insulins in late-stage development
- Develop a comprehensive, individualized evidence-based treatment plan for patients with type 2 diabetes who require basal insulin that incorporates best practices for initiation, dosing, and titration
Reserve Your Seat Today & Earn up to 1.0 AMA, ABIM MOC, AAPA, ANCC, IPCE credit/contact hour for FREE!
In-Person Registration
Dates & Locations:
10/6/26 – Chicago, IL | 5:30 – 7:00 PM CT
Maggiano’s Little Italy
516 N Clark St., Chicago, IL 60654
11/18/26 – Minneapolis, MN | 5:30 – 7:00 PM CT
CRAVE Food & Drink LaSalle Plaza-Minneapolis
825 Hennepin Ave, Minneapolis, MN 55402
This activity is designed for Endocrinologists and endocrinology-focused NPs and PAs who care for patients with T2D in the United States.
- Introduction
- Assessing The Current Limitations of Basal Insulin and Emerging Role of Novel Therapies
- Evaluating Efficacy and Safety of Weekly Basal Insulins
- Developing and Implementing Comprehensive Treatment Plans
- Conclusion
After completing this activity, the participant should be better able to:
Differentiate emerging once-weekly basal insulins from traditional once-daily formulations based on molecular structure, mechanism of action, and pharmacokinetic/pharmacodynamic properties
Interpret the efficacy and safety data of once-weekly basal insulins in late-stage development
Develop a comprehensive, individualized evidence-based treatment plan for patients with type 2 diabetes who require basal insulin that incorporates best practices for initiation, dosing, and titration
This activity is provided by MLI

Accreditation, Support and Credit

In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
PA
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
MIPS
Completion of this accredited CE activity will meet the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
Support Statement
This activity is supported by an educational grant from Lilly.
Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner/Presenter
Julio Rosenstock, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Amgen, Applied Therapeutics, Arrowhead, Biomea Fusion, Boehringer Ingelheim, Corcept, Eccogene, Hanmi, i2O Therapeutics, Lilly, Novo Nordisk, Regeneron, Roche, Sanofi, Structure Therapeutics, Terns
Speaker/Member of Speaker’s Bureau: Received honoraria for lectures: Lilly, Novo Nordisk, Sanofi
Research Funding/Support: All have ended: Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Corcept, Corxel, Hanmi, Lilly, Merck, Novo Nordisk, Pfizer, Regeneron, Roche, Regor, Sanofi, Structure Therapeutics, Terns
Planner/Presenter
Marc-André Cornier, MD, has a financial interest/relationship or affiliation in the form of:
Planner/Presenter
Jennifer Green, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Bayer, Boehringer Ingelheim, Corcept, Idorsia, Lilly, Merck, Mineralys, Novo Nordisk, Sparrow, Valo, Vertex, Zealand
Research Funding (to institution): Boehringer Ingelheim, COUR, GentiBio, Merck, Metsera
Patient
Ronnie Williams has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, does not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity, however, registration is required. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
About This Activity
Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
Copyright © 2026 Medical Learning Institute Inc. All Rights Reserved.
